会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Furoxan compounds, compositions and methods of use
    • 呋喃糖化合物,组合物和使用方法
    • US07838023B2
    • 2010-11-23
    • US12093561
    • 2006-11-16
    • David S. GarveyRamani R. Ranatunge
    • David S. GarveyRamani R. Ranatunge
    • A61K9/00A61K31/4245A61K31/502A61K33/00A61P9/00C07D271/08
    • C07D271/08
    • The invention provides novel furoxan compounds, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for (a) treating cardiovascular diseases; (b) inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device; (c) treating pathological conditions resulting from abnormal cell proliferation; (d) treating transplantation rejections, (e) treating autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; (f) reducing scar tissue or for inhibiting wound contraction; (g) treating diseases resulting from oxidative stress; (h) treating endothelial dysfunctions; and (j) treating diseases caused by endothelial dysfunctions.
    • 本发明提供新的呋喃糖化合物或其药学上可接受的盐,以及包含至少一种化合物和任选的至少一种一氧化氮增强化合物和/或至少一种治疗剂的新组合物。 本发明的化合物和组合物也可以结合到基质上。 本发明还提供了(a)治疗心血管疾病的方法; (b)抑制由血液暴露于医疗器械引起的血小板聚集和血小板粘附; (c)治疗由异常细胞增殖引起的病理状况; (d)治疗移植排斥,(e)治疗自身免疫性,炎症性,增殖性,过度增殖性或血管性疾病; (f)减少瘢痕组织或抑制伤口收缩; (g)治疗由氧化应激引起的疾病; (h)治疗内皮功能障碍; 和(j)治疗由内皮功能障碍引起的疾病。
    • 8. 发明授权
    • Cyclooxygenase-2 selective inhibitors, compositions and methods of use
    • 环氧合酶-2选择性抑制剂,组合物和使用方法
    • US07244753B2
    • 2007-07-17
    • US10628375
    • 2003-07-29
    • David S. GarveySubhash P. KhanapureRamani R. RanatungeStewart K. RichardsonJoseph D. Schroeder
    • David S. GarveySubhash P. KhanapureRamani R. RanatungeStewart K. RichardsonJoseph D. Schroeder
    • A61K31/427A61K31/422A61K31/4015C07D417/02C07D413/02
    • C07D213/55C07D213/50C07D231/12C07D231/14
    • The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.
    • 本发明描述了新型环氧合酶2(COX-2)选择性抑制剂和包含至少一种环氧合酶2(COX-2)选择性抑制剂的新型组合物,以及任选地至少一种捐赠,转移或释放一氧化氮的化合物,刺激内源性合成 的一氧化氮,提高内源性内源性释放因子水平,或者是一氧化氮合酶的底物和/或至少一种治疗剂。 本发明还提供了包含至少一种COX-2选择性抑制剂,任选地亚硝基化和/或亚硝基化的新的试剂盒,以及任选的至少一种一氧化氮供体,和/或任选的至少一种治疗剂。 本发明的新型环加氧酶2选择性抑制剂可以任选地亚硝化和/或亚硝化。 本发明还提供了治疗炎症,疼痛和发烧的方法; 用于治疗和/或改善COX-2选择性抑制剂的胃肠性质; 促进伤口愈合; 用于治疗和/或预防肾和/或呼吸毒性; 用于治疗和/或预防由环氧合酶-2水平升高引起的其他疾病; 并用于改善COX-2选择性抑制剂的心血管外形。